EUVIMEDEUVIMED entdecken
Editorial

Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?

Thiago A Miranda, Daniel M Girardi, Allan A L Pereira

Chinese Clinical Oncology · 2024

DOI: 10.21037/cco-23-106 ↗

Kurz gefasst

Editorial in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von Thiago A Miranda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Nivolumab, Pyridines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNivolumabPyridinesAnilidesIpilimumabHumansAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Hepatocellular carcinoma (HCC)cabozantinibimmunotherapyipilimumabnivolumab

Substanzen

cabozantinibNivolumabPyridinesAnilidesIpilimumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil.
  • Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Zitieren

APA

Miranda, T. A., Girardi, D. M., & Pereira, A. A. L. (2024). Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?. Chinese Clinical Oncology. https://doi.org/10.21037/cco-23-106

Vancouver

Miranda TA, Girardi DM, Pereira AAL. Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?. Chinese Clinical Oncology. 2024. doi:10.21037/cco-23-106

BibTeX
@article{Miranda2024,
  author = {Miranda, Thiago A and Girardi, Daniel M and Pereira, Allan A L},
  title = {Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?},
  journal = {Chinese Clinical Oncology},
  year = {2024},
  doi = {10.21037/cco-23-106}
}
Kostenlos starten →